Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares traded up 3.8% during mid-day trading on Thursday . The stock traded as high as $3.32 and last traded at $3.29, with a volume of 62,420 shares traded. The stock had previously closed at $3.17.

Several research analysts have issued reports on the stock. Chardan Capital lowered their price target on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a report on Monday. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Friday, August 5th. Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Thursday, June 30th. Stifel Nicolaus lowered their price objective on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, June 30th. Finally, Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research note on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $11.85.

The firm’s market capitalization is $68.60 million. The company’s 50 day moving average price is $3.27 and its 200 day moving average price is $4.45.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Equities research analysts forecast that Dicerna Pharmaceuticals Inc. will post ($3.21) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.